Since 1995, the KEMRI–Wellcome Trust Research Programme has quietly reshaped the global fight against malaria not through a single breakthrough, but through a sustained commitment to evidence, context, and people. Its work offers a powerful lesson: defeating malaria is not just about tools, but about understanding systems, adapting strategies, and investing in local science.
In the 1990s, malaria control was often guided by broad assumptions and limited data. At the time, much of sub-Saharan Africa was treated as a homogeneous block of high transmission. What emerged from Kilifi challenged that view. By embedding research within a functioning hospital and linking it to long-term community surveillance, the programme demonstrated that malaria is not a single disease experience but a spectrum from mild illness to life-threatening syndromes such as cerebral malaria and severe anaemia. This reframing mattered. It shifted attention toward targeted clinical care and evidence-based definitions that are now used globally.
Yet perhaps the most important early insight was this: context determines impact. Interventions do not succeed simply because they work in theory they succeed when they fit into real lives. This principle underpinned one of the programme’s most influential contributions: the demonstration that insecticide-treated bed nets significantly reduce child mortality. While bed nets may now seem like an obvious solution, their widespread adoption required rigorous local evidence. Similarly, our research on intermittent preventive treatment in pregnant women and infants showed that timing, delivery systems, and population targeting are as important as the drugs themselves.
These lessons remain deeply relevant today. Too often, global health still seeks universal solutions to deeply local problems. The Kilifi experience suggests a different model—one where interventions are continuously tested, adapted, and refined within the communities they are meant to serve.
As malaria control efforts scaled up in the 2000s, a new challenge emerged: how to allocate resources efficiently in the face of constrained funding. Here again, the programme led a paradigm shift. Through initiatives such as the Malaria Atlas Project, it demonstrated that malaria risk varies dramatically not just between countries, but within them. This insight fundamentally changed how we think about malaria control. Instead of blanket approaches, it became possible to design precision public health strategies, targeting high-burden areas while avoiding overinvestment in low-risk regions.
This shift toward data-driven decision-making has only grown more important. Today, as climate change, urbanization, and population movement reshape disease patterns, static models of malaria transmission are no longer sufficient. What is needed is continuous, high-resolution intelligence something the programme has been building for decades.
At the same time, the limitations of existing tools have become clearer. Up to 20 percent of children admitted with severe malaria still die despite treatment with fast-acting drugs that rapidly reduce parasitemia, underscoring the need for improved supportive care. Meanwhile, drug resistance continues to threaten treatment efficacy, while insecticide resistance challenges vector control strategies. We have contributed to the development of the two recently approved malaria vaccines, RTS,S and R21, which are currently being rolled out to protect infants in high-transmission areas. While these vaccines are not perfect, they will help reduce the overall burden of malaria. These realities point to a sobering conclusion: there is no single “silver bullet” for malaria.
But this is not a failure it is a call for a more integrated approach. The strength of the KEMRI–Wellcome Trust Research Programme lies precisely in its accumulated experience and its capacity to bridge disciplines in pursuit of solutions to complex health challenges: clinical medicine, epidemiology, genomics, and social science. Its work on immunity and host genetics is a reminder that biology resists simple answers; its research on health systems and community behaviour reminds us that implementation is equally demanding. Meeting these challenges requires the same rigour, creativity, and collaboration that has defined the Programme's work from the outset.
Looking ahead, three priorities emerge from this body of work.
First, invest in local research ecosystems. One of the programme’s most enduring contributions has been its role in training African scientists and building sustainable research capacity. This is not just a matter of equity—it is a strategic necessity. Local researchers are best positioned to understand context, build trust, and respond rapidly to emerging challenges.
Second, embrace adaptive, data-driven strategies. Malaria control must move beyond static plans toward dynamic systems that can respond to changing clinical presentations, parasite transmission and resistance patterns, and population needs. This shift requires sustained investment in surveillance, data integration, and analytical capacity, including both human capital and technical infrastructure.
Third, bridge the gap between evidence and policy. The programme’s influence on global and national guidelines demonstrates what is possible when research is closely aligned with decision-making. However, this alignment cannot be taken for granted. It requires ongoing collaboration, communication, and a willingness to act on evolving evidence.
The story of malaria research in Kilifi is ultimately a story of persistence. Progress has not come from a single discovery, but from decades of incremental advances, each building on the last. It is also a story of humility of recognizing that complex problems demand nuanced solutions.
As the global health community renews its commitment to malaria elimination, the lessons from the KEMRI–Wellcome Trust Research Programme are clear. Success will depend not only on new technologies, but on how well we understand the environments in which they are deployed. It will depend on whether we invest in people as much as in products. And above all, it will depend on our ability to learn, adapt, and act on evidence.
From Kilifi to the world, the message is simple but profound: the future of malaria control is not just about innovation it is about integration, intelligence, and local leadership.
At the center of this work are scientists whose research is shaping strategies to reduce infections and save lives across Africa and beyond.
Among the notable names are Prof. Isabella Oyier, Prof. Francis Ndungu, Dr. Abdirahman Abdi and Dr. Marta Maia, whose work spans molecular epidemiology, immunology, host-parasite interactions and vector control.
Prof. Isabella Oyier heads the Biosciences Department at the KEMRI-Wellcome Trust Research Programme (KWTRP). She is also a professor of molecular epidemiology at the University of Oxford’s Nuffield Department of Medicine, a Calestous Juma Fellow funded by the Bill & Melinda Gates Foundation, and a Global Research Fellow at Reuben College, Oxford.
Her research focuses on Plasmodium falciparum malaria, the deadliest malaria parasite affecting humans. She uses molecular tools to track genetic changes in parasite antigens that could be targeted by vaccines, measure the complexity of infections, distinguish reinfections from persistent infections, and monitor markers of drug resistance. Her work is helping scientists stay ahead of a parasite known for adapting quickly to medicines and control efforts.
Prof. Francis Ndungu is widely recognized for his work on malaria immunity and vaccine development. His research examines how immunological memory develops in people previously exposed to malaria, why some children suffer repeated malaria episodes more than others, and how semi-immune adults naturally control parasite growth and inflammation after infection.
These studies are offering valuable insights into how vaccines can trigger protective immune responses in populations living in malaria-endemic regions, where repeated exposure to the disease often shapes immunity in complex ways.
Dr. Abdirahman Abdi is investigating how malaria parasites interact with the human body and trigger severe disease. His research centers on extracellular vesicles tiny particles released by cells that carry proteins and genetic material used for communication between cells.
By studying these vesicles, Dr. Abdi seeks to understand how parasites manipulate human immune responses and cause severe malaria. His work combines genomics, transcriptomics, proteomics and metabolomics with cellular immunology to identify new intervention targets. His studies have been supported by Wellcome Trust fellowships.
Dr. Marta Maia is leading innovative efforts in malaria vector control, combining laboratory, insectary and field-based research to develop new tools for mosquito surveillance and prevention.
Her team is studying ivermectin as an endectocide for malaria control through mass drug administration campaigns in East and Southern Africa. They are also investigating Microsporidia MB, a naturally occurring microbe that can block malaria transmission in mosquitoes, as part of the ANTIVEC Network.
In addition, her group is advancing the use of MALDI-TOF mass spectrometry as a fast and affordable tool for identifying mosquito traits important for disease surveillance.
Together, these scientists represent Kenya’s growing influence in global malaria research. Their discoveries are contributing to the development of better vaccines, stronger medicines and smarter mosquito control strategies at a time when malaria remains one of Africa’s biggest public health challenges.